1h Free Analyst Time
The doxorubicin market is forecasted to grow by USD 497.4 million during 2023-2028, accelerating at a CAGR of 6.09% during the forecast period. The report on the doxorubicin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of cancer cases, increasing product launches of doxorubicin, and advancements in diagnostic methods.
The doxorubicin market is segmented as below:
By Formulation
- Lyophilized powder
- Doxorubicin injection
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the doxorubicin market covers the following areas:
- Doxorubicin market sizing
- Doxorubicin market forecast
- Doxorubicin market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Formulation
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global doxorubicin market: Aurobindo Pharma Ltd., Baxter International Inc., Cipla Inc., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Meiji Holdings Co. Ltd., Merck KGaA, Mitsui and Co. Ltd., Novartis AG, Pfizer Inc., Pharmagen CZ s.r.o, S. G. Biopharm Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Synbias Pharma AG, Teva Pharmaceutical Industries Ltd., TTY Biopharm Co. Ltd., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is introduction of precision cancer medicine."
According to the report, one of the major drivers for this market is the growing prevalence of cancer cases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurobindo Pharma Ltd.
- Baxter International Inc.
- Cipla Inc.
- Dr Reddys Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Hikma Pharmaceuticals Plc
- Intas Pharmaceuticals Ltd.
- Johnson and Johnson Services Inc.
- Meiji Holdings Co. Ltd.
- Merck KGaA
- Mitsui and Co. Ltd.
- Novartis AG
- Pfizer Inc.
- Pharmagen CZ s.r.o
- S. G. Biopharm Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Synbias Pharma AG
- Teva Pharmaceutical Industries Ltd.
- TTY Biopharm Co. Ltd.
- Zydus Lifesciences Ltd.
